Handelsman, D J Conway, A J Howe, C J Turner, L Mackey, M A
Published in
The Journal of clinical endocrinology and metabolism
Clinical research conducted in Australia suggests that a progestin-androgen combination depot has potential for hormonal male contraception. The authors' previous research had indicated that 6 200-mg testosterone enanthate pellets implanted subdermally produced substantial reductions over injections in the delivered testosterone dose while maintain...
Bassol, S Hernandez, C Nava, M P Trujillo, A M Luz de la Cruz, D
Published in
Contraception
At the family planning clinic of the medical school in Coahuila, Mexico, providers recruited 11 volunteers requesting an injectable contraceptive into Group I (Mesigyna: 50 mg norethisterone enanthate + 5 mg estradiol valerate) and 10 similar volunteers into Group II (Cyclofem: 25 mg medroxyprogesterone acetate + 25 mg estradiol cypionate). After t...
Kaunitz, A M
Published in
American journal of obstetrics and gynecology
Depot medroxyprogesterone acetate (DMPA) is the only injectable contraceptive available in the United States. After more than 20 years of regulatory review, the Food and Drug Administration approved DMPA for contraceptive use in 1992 after the publication of reassuring data about its possible association with breast cancer. It has been used by 30 m...
Anwar, M Soejono, S K Maruo, T Abdullah, N
Published in
Asia-Oceania journal of obstetrics and gynaecology / AOFOG
In Indonesia, researchers compared data on 25 women, 18-40 years old, using the subdermal levonorgestrel (LNG) implant (Norplant) with 25 women, 18-40 years old, using the depot-medroxyprogesterone acetate (DMPA) injectable (Depo-Provera) to evaluate the effects of these 2 long acting contraceptive methods on lipid metabolism. (Norplant releases ab...
Kekkonen, R Lähteenmäki, P Luukkainen, T Tuominen, J
Published in
Fertility and sterility
To assess the effectiveness of an estrogen-free oral contraceptive (OC) involving the sequential administration of an antiprogesterone and synthetic progestin, 11 healthy Finnish women 20-34 years of age were enrolled in a prospective investigation for 1-3 cycles. 25 mg of RU-486 was administered for the first 21 days of the cycle, followed by 5 mg...
Costa, T H Dorea, J G
Published in
Annals of tropical paediatrics
Researchers compared data on 22 women using either a barrier method or a natural family planning method or had undergone female sterilization (controls) with data on 89 women using either a low dose combined oral contraceptive (OC), a medium dose combined OC, a low dose progestin only OC, the injectable Depo-Provera, or an IUD to examine the hormon...
van den Berg, H W Martin, J Lynch, M
Published in
British journal of cancer
After an initial response to hormonal therapy, breast cancer patients whose tumors are positive for the presence of estrogen receptors and progesterone receptors become resistant to this treatment, either because of the development of antiestrogen withdrawal. Within 5 days of transfer to an estrogen-free medium, proliferation of ZR-75-1 cells slowe...
Berga, S L Yen, S S
Published in
Clinical endocrinology
To determine whether the disordered patterns of luteinizing hormone (LH) pulsatility and impaired opioidergic regulation of gonadotropin- releasing hormone (GnRH)-LH observed in women with polycystic ovarian syndrome reflect an inherent hypothalamic abnormality or a functional state related to the acyclycity of sex steroids, medroxyprogesterone ace...
Thijssen, J H
Published in
Annals of the New York Academy of Sciences
Researchers in Utrecht, the Netherlands have studied the effects of different factors, such as oral contraceptives (OCs), on sex hormone binding globulin (SHBG) levels in blood. The SHBG levels in women who continuously used OCs consisting only of .05 mg of ethinyl estradiol (EE2) rose as high as 260% + or - 25% of those in women not using OCs. Fur...
Fotherby, K Howard, G
Published in
Journal of obstetrics and gynaecology
2 recent studies largely dispel concern about the restoration of fertility after discontinuation of injectable contraceptives. After cessation of use of depot medroxyprogesterone acetate (DMPA) or norethisterone enanthate there is some delay in fertility restoration, but fertility is not impaired once the progestogen is cleared from the body. Pharm...
